InjectionClinical Overview
Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered intravenously by slow injection over 3-5 minutes or continuous/intermittent infusion over 30-60 minutes by qualified medical staff after reconstitution with Water for Injections.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Phlebitis at infusion site, diarrhea, nausea, vomiting, rash, elevated liver enzymes. Rare/Severe: Severe hypersensitivity, neutropenia, thrombocytopenia, and neurotoxicity in renal patients.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in patients allergic to cephalosporins or beta-lactamase inhibitors. Requires strict dose titration in renal dysfunction.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Ceftazidime Injection 1g
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Ceftazidime Injection 250mg
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Ceftazidime Injection 500mg
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Piperacillin 4000mg + Tazobactum 500mg Injection
Piperacillin and Tazobactam is an extended-spectrum ureidopenicillin combined with a beta-lactamase inhibitor. Piperacillin exhibits potent bactericidal activity against Pseudomonas aeruginosa, Enterobacteriaceae, and anaerobes by inhibiting cell wall synthesis, while tazobactam inactivates plasmid- and chromosomally-mediated beta-lactamases. Indicated for nosocomial and severe community-acquired pneumonia, complicated intra-abdominal infections, complicated skin/soft tissue infections, febrile neutropenia, and complicated urinary tract infections.